Expanding the clinical development of bevacizumab

Oncologist

Volumn 9, Issue SUPPL. 1, 2004, Pages 27-35

  Chen, Helen X ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bevacizumab; Cancer; Clinical trial; Monoclonal antibody; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ESTRAMUSTINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; IMATINIB; INTERLEUKIN 2; IRINOTECAN; MITOXANTRONE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PEGINTERFERON ALPHA2A; RITUXIMAB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; SURVIVAL TIME; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; FEMALE; FORECASTING; GENITAL NEOPLASMS, FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 2942627177     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-suppl_1-27     Document Type: Conference Paper

References (78)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
2. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
3. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-1364.
4. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-4599.
5. Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999;288:371-378.
6. Mordenti J, Thomsen K, Licko V et al. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 1999;27:14-21.
7. Hu L, Hofmann J, Zaloudek C et al. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161:1917-1924.
8. Gorski DH, Beckett MA, Jaskowiak NT et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-3378.
9. Lee CG, Heijn M, di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-5570.
10. Hotz HG, Hines OJ, Hotz B et al. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J Gastrointest Surg 2003;7:220-228.
11. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
12. Sledge G, Miller K, Novony W et al. A phase II trial of single-agent rHumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc Am Soc Clin Oncol 2000;19:3a.
13. Miller KD, Rugo HS, Cobleigh MA et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. San Antonio Breast Cancer Symposium 2002;35a.
14. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. The Oncologist 2004;9(suppl 1):11-18.
15. Herbst RS, Sandler AB. Non-small cell lung cancer and anti-angiogenic therapy: what can be expected of bevacizumab? The Oncologist 2004;9(suppl 1):19-26.
16. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer: results of a randomized phase III trial. N Engl J Med 2004 (in press).
17. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. The Oncologist 2004;9(suppl 1):36-42.
18. Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. The Oncologist 2004;9(suppl 1):43-49.
19. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001;2:667-673.
20. Motzer RJ, Mazumdar M, Bacik J et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:1928-1935.
21. Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338:1272-1278.
22. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999;353:14-17.
23. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859-2867.
24. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. JAMA 1995;273:564-570.
25. Iliopoulos O, Levy AP, Jiang C et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595-10599.
26. Takahashi A, Sasaki H, Kim SJ et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54:4233-4237.
27. O'Byrne KJ, Dobbs N, Propper D et al. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 1999;353:1494-1495.
28. Sato K, Tsuchiya N, Sasaki R et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 1999;90:874-879.
29. Kanayama H, Yano S, Kim SJ et al. Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice. Clin Exp Metastasis 1999;17:831-840.
30. Hazelton DA, Hamilton TC. Vascular endothelial growth factor in ovarian cancer. Curr Oncol Rep 1999;1:59-63.
31. Hartenbach EM, Olson TA, Goswitz JJ et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997;121:169-175.
32. Paley PJ, Staskus KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106.
33. Yamamoto S, Konishi I, Mandai M et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221-1227.
34. Duyndam MC, Hilhorst MC, Schlüper HM et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 2002;160:537-548.
35. Nakanishi Y, Kodama J, Yoshinouchi M et al. The expression of vascular endothelial growth factor and transforming growth factor-β associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol Pathol 1997;16:256-262.
36. Yoneda J, Kuniyasu H, Crispens MA et al. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90:447-454.
37. Gossmann A, Helbich TH, Mesiano S et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 2000;183:956-963.
38. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-1256.
39. Kerbel RS, Viloria-Petit A, Klement G et al. 'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000;36:1248-1257.
40. Fidler IJ, Ellis LM. Chemotherapeutic drugs-more really is not better. Nat Med 2000;6:500-502.
41. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-R24.
42. Fujiwaki R, Hata K, Iida K et al. Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis. Anticancer Res 2000;20:1317-1322.
43. Obermair A, Bancher-Todesca D, Bilgi S et al. Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89:1212-1217.
44. Duque JL, Loughlin KR, Adam RM et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523-527.
45. Strohmeyer D, Rössing C, Bauerfeind A et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000;45:216-224.
46. Ferrer FA, Miller LJ, Lindquist R et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999;54:567-572.
47. Jackson MW, Roberts JS, Heckford SE et al. A potential autocrine role for vascular endothelial growth factor in prostate cancer. Cancer Res 2002;62:854-859.
48. Reese DM, Fratesi P, Corry M et al. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate J 2001;3:65-70.
49. Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-4166.
50. Gabrilovich DI, Ishida T, Nadaf S et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-2970.
51. Arii S, Mori A, Uchida S et al. Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999;12:25-30.
52. Shimada H, Hoshino T, Okazumi S et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86:552-557.
53. Smith BD, Smith GL, Carter D et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:780-785.
54. Hui EP, Chan AT, Pezzella F et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002;8:2595-2604.
55. Tuttle RM, Fleisher M, Francis GL et al. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002;87:1737-1742.
56. Wendt TG, Grabenbauer GG, Rodel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324.
57. Ando S, Nojima K, Majima H et al. Evidence for mRNA expression of vascular endothelial growth factor by X-ray irradiation in a lung squamous carcinoma cell line. Cancer Lett 1998;132:75-80.
58. Gupta VK, Jaskowiak NT, Beckett MA et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002;8:47-54.
59. National Cancer Institute. Annual cancer statistics review 1973-1988. Bethesda, MD: Department of Health and Human Services, 1991.
60. Seo Y, Baba H, Fukuda T et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88:2239-2245.
61. Ellis LM, Takahashi Y, Fenoglio CJ et al. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998;34:337-340.
62. von Marschall Z, Cramer T, Hocker M et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 2000;119:1358-1372.
63. Buchler P, Reber HA, Buchler MW et al. VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg 2002;236:738-749.
64. Itakura J, Ishiwata T, Shen B et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000;85:27-34.
65. Kindler HL, Ansari R, Lester E et al. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 2003;22(suppl 1):259.
66. Dezube BJ. The role of human immunodeficiency virus-I in the pathogenesis of acquired immunodeficiency syndrome-related Kaposi's sarcoma: the importance of an inflammatory and angiogenic milieu. Semin Oncol 2000;27:420-423.
67. Lazar-Molnar E, Hegyesi H, Toth S et al. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000;12:547-554.
68. Bentley SA. Bone marrow connective tissue and the haemopoietic microenvironment. Br J Haematol 1982;50:1-6.
69. Aguayo A, Kantarjian H, Manshouri T et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245.
70. Bellamy WT, Richter L, Frutiger Y et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733.
71. Dankbar B, Padro T, Leo R et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-2636.
72. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003;81:20-31.
73. Bellamy WT, Richter L, Sirjani D et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-1434.
74. Dias S, Hattori K, Heissig B et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 2001;98:10857-10862.
75. Perez-Atayde AR, Sallan SE, Tedrow U et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-821.
76. Aguayo A, Estey E, Kantarjian H et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-3721.
77. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol 2001;28:560-564.
78. List AF. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. The Oncologist 2001;6(suppl 5):24-31.